Corruption in the Pharmaceutical Trade BAYER AG As an opener to this article that describes very directly what the corporate world of pharmaceuticals is about, I would like to quote Marijn Dekkers, CEO of Bayer AG, December 3, 2013 – “We did not develop this medicine for Indians. We developed it for Western patients who can afford it.” The original Businessweek article has been removed from the internet, including its internet cache and the video that was on ft-live.com . https://www.keionline.org/node/1924 , http://www.dailymail.co.uk/news/article-2545360/Pharmaceutical-chief-tries-stop-India-replicating-cancer-treatment.html Bayer AG can trace its roots back to August 1863 with the creation of “Friedr.Bayer et comp”, a partnership between businessman Friederich Bayer, and Johann Friederich Weskott, a master dyer. This company would specialize in the manufacture of synthetic dyes and was based in Barmen, now part of Wuppertal in Germany. The company grew quickly, exporting dyes a...
Johnson & Johnson - $3,38 Billion in Fines By Ronald Gibson 24 July 2017 Johnson & Johnson, an American based medical devices, pharmaceutical and consumer packaged goods manufacturing company, was founded in 1886 by brothers Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, based on the idea to manufacture a line of ready-to-use surgical dressings. Two years later J&J pioneered the use of the first commercial first aid kits designed to help railroad workers, but soon became widely used to treat injuries by both corporate and household consumers. 1894 Marked the year in which J&J entered the soon to be lucrative baby business by selling maternity kits and the ever famous J&J Baby Powder. Johnson & Johnson grew and expanded to include companies and brands like Ethicon (surgical sutures and wound closure devices), McNeil Consumer Healthcare (over-the-counter and prescription medicines like Tylenol), Janssen-Cilag (prescription medicines),...
#MedicalMisconduct - Novartis Misconduct in the Pharmaceutical Sector - Novartis By Ronald Gibson 12 July 2017 As the South African Government and Novartis recently signed a memorandum of understanding relating to pharmaceutical research for the development of new medicinal compounds in South Africa, I decided to do my first article covering misconduct in the pharmaceutical sector about Novartis, as we need to have an idea of the ethics we might expect from them. I will mainly focus on information related to their business dealings in the USA, as there are quite a few Government Oversight institutions and non-profit consumer protection bodies that keep track of companies in the USA. Novartis was formed in 1996 after the merger of Ciba-Geigy and Sandoz. Both these companies started off in the production of synthetic fabric dyes, later branching off into pharmaceuticals and agricultural chemicals. During the merger the pharmaceutical and agrochemical divisions of both companies fo...
Comments
Post a Comment